How effective is durvalumab in immunotherapy?

Durvalumab/Durvalumab is an immune checkpoint inhibitor that specifically blocks the binding of programmed death ligand 1 (PD-L1) and its receptor PD-1 to relieve the suppression of the immune system by tumor cells, thereby restoring the anti-tumor activity of T cells. As an anti-PD-L1 antibody, durvalumab has shown significant efficacy in the immunotherapy of multiple cancer types, especially in the treatment areas of small cell lung cancer, non-small cell lung cancer (NSCLC) andbladder cancer. Clinical trials have shown that durvalumab can prolong the progression-free survival (PFS) and overall survival (OS) of patients, is well tolerated, and has controllable side effects.

In patients with locally advanced unresectable non-small cell lung cancer,The PACIFIC study is a key trial for the application of durvalumab. This study shows that after patients complete radiotherapy and chemotherapy, maintenance treatment with durvalumab can significantly reduce the risk of disease progression and improve survival prognosis. This discovery changed the treatment paradigm for advanced NSCLC, making immunotherapy a standard first-line maintenance treatment option. In addition, durvalumab has also shown positive efficacy in patients with urothelial cancers such as bladder cancer, prolonging progression-free survival and improving quality of life.

However, the efficacy of immunotherapy is closely related to the patient's tumor microenvironment,PD-L1 expression level and the patient's individual immune status. Although durvalumab has good anti-tumor activity, not all patients can benefit, and some patients may suffer from immune-related adverse reactions. Overall, durvalumab provides new hope for patients with a variety of advanced tumors in the field of immunotherapy, and is especially suitable for patients who require long-term maintenance therapy and have good tolerance.

Reference materials:https://www.imfinzi.com/